HomeAI · summaries
Storia in 3 fonti
Europe's CHMP gives thumbs up to AZ's breast cancer drug after thumbs down from FDA adcomm
Less than a month after an FDA advisory committee voted 6-3 | Less than a month after an FDA advisory committee recommended rejection of AstraZeneca’s novel cancer drug, Europe’s CHMP has blessed Etcamah with a positive opinion. The EMA also has signed off on Novo Nordisk's Wegovy pill.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
Roche narrowly edges out AstraZeneca for the top-rated oncology MSL team: survey
Roche/Genentech and AstraZeneca have the best-performing medical science liaison (MSL) teams in oncology, according to a ZoomRx survey of physicians. | Roche/Genentech and…
- ·
With Voxzogo under pressure, BioMarin touts trial win in label expansion bid
With phase 3 results that have “exceeded” BioMarin’s expectations, according to R&D chief Greg Friberg, M.D., the California biotech appears set up to gain a label expansion for…
